These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
26. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720 [TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES Clin Transpl; 2009; ():475-8. PubMed ID: 20524318 [TBL] [Abstract][Full Text] [Related]
29. Role of proteasome inhibition in sensitized transplant candidates. Everly MJ; Everly JJ; Terasaki PI Chin Med J (Engl); 2011 Mar; 124(5):771-4. PubMed ID: 21518574 [TBL] [Abstract][Full Text] [Related]
30. Bortezomib: a new player in pre- and post-transplant desensitization? Lemy A; Toungouz M; Abramowicz D Nephrol Dial Transplant; 2010 Nov; 25(11):3480-9. PubMed ID: 20826741 [TBL] [Abstract][Full Text] [Related]
31. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384 [TBL] [Abstract][Full Text] [Related]
32. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
33. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843 [TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
36. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302 [TBL] [Abstract][Full Text] [Related]
37. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C Clin Transpl; 2009; ():433-8. PubMed ID: 20524311 [TBL] [Abstract][Full Text] [Related]
38. Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies. Ticehurst EH; Molina MR; Frank R; Kearns J; Lal P; Goldberg LR; Tsai D; Wald J; Kamoun M Clin Transpl; 2011; ():409-14. PubMed ID: 22755439 [TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment. Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA Clin Transpl; 2009; ():415-20. PubMed ID: 20524307 [TBL] [Abstract][Full Text] [Related]
40. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant. Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]